Want to join the conversation?
John Roberts of UBS asks about the EU's antitrust review on the proposed $MON-Bayer deal and the regulatory regime. CEO Hugh Grant said the review is more of a declaration of intent and focuses more on the intention of going forward with the deal.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?